Drug Profile

Futibatinib - Taiho Oncology/Taiho Pharmaceutical

Alternative Names: LYTGOBI; Lytgobi; TAS 120

Latest Information Update: 10 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Taiho Pharmaceutical
Developer Taiho Oncology; Taiho Pharmaceutical
Class Amines; Antineoplastics; Ketones; Phenyl ethers; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cholangiocarcinoma
New Molecular Entity Yes

Marketed Biliary cancer; Cholangiocarcinoma
Phase II/III Cancer
Phase II Breast cancer; Gastric cancer; Lymphoid leukaemia; Myeloid leukaemia; Oesophageal cancer; Solid tumours; Urogenital cancer
Phase I/II Non-small cell lung cancer
Preclinical Rhabdomyosarcoma

03 Dec 2025 Launched for Cholangiocarcinoma (Metastatic disease, Late-stage disease, Second-line therapy or greater) in United Kingdom (PO)
19 Sep 2025 Taiho Oncology terminates a phase II trial in Lymphoid leukaemia, Gastric cancer, Solid tumours, Myeloid leukaemia (In adults, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, South Korea, Japan, Netherlands, USA, Portugal, Italy, France, Germany, Hong Kong, Singapore, Spain, Sweden, Turkey, United Kingdom (PO) due to enrollment challenges (NCT04189445)
23 Jan 2025 Efficacy, pharmacodynamic and adverse events data from phase Ib trial in Oesophageal cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GI-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com